IPO registrations (S-1, F-1) · Registrants
Athenex, Inc.
- SEC CIK
- 1300699 · filings on EDGAR ↗
- Former names
- Kinex Pharmaceuticals, Inc. (2013–2015); Kinex Pharmaceuticals LLC (2004–2012)
- Registration
- Form S-1, first filed 2017-05-12, last 2018-01-22; 2 initial registrations, 3 amendments
- Outcome
- Final prospectus filed 2017-06-15; declared effective 2017-06-13
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 1001 MAIN STREET, SUITE 600, Buffalo, NY 14203
- EIN
- 43-1985966
- EDGAR entity type
- operating
- Insiders and CEO pay
- Athenex, Inc. on the corporate pages
Offering terms
- Proposed price range
- $11.00–$13.00 per share (S-1/A filed 2017-06-02)
- Final price
- $11.00 per share, within the range (424B4 filed 2017-06-15, an initial public offering)
- Shares sold
- 6,000,000
- Gross proceeds
- $66,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol ATNX
- Lead underwriters
- Credit Suisse; Deutsche Bank; J.P. Morgan
- Syndicate
- ICBC International
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: ATHENEX, INC Fuzzy (name and state)
- Business registration: ATHENEX, LLC Fuzzy (name and state)
- Form 5500 plan sponsor: ATHENEX, INC. EXACT (EIN (EXACT))
- Form D issuer: Athenex, Inc. EXACT (CIK (EXACT))
- SEC filer: Athenex, Inc. EXACT (CIK (EXACT))
- Person page: Steven J Adams Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Officer))
Filings 9
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2017-05-12 | S-1 | S-1 (registration) | Athenex, Inc. | 0001193125-17-168575 ↗ |
| 2017-05-18 | S-1/A | S-1/A (amendment) | Athenex, Inc. | 0001193125-17-175232 ↗ |
| 2017-06-02 | S-1/A | S-1/A (amendment) | Athenex, Inc. | 0001193125-17-193190 ↗ |
| 2017-06-13 | EFFECT | EFFECT (declared effective) | Athenex, Inc. | 9999999995-17-001520 ↗ |
| 2017-06-15 | 424B4 | 424B4 (final prospectus) | Athenex, Inc. | 0001193125-17-204746 ↗ |
| 2018-01-22 | S-1 | S-1 (registration) | Athenex, Inc. | 0001193125-18-015259 ↗ |
| 2018-01-22 | S-1/A | S-1/A (amendment) | Athenex, Inc. | 0001193125-18-015813 ↗ |
| 2018-01-24 | EFFECT | EFFECT (declared effective) | Athenex, Inc. | 9999999995-18-000213 ↗ |
| 2018-01-25 | 424B4 | 424B4 (final prospectus) | Athenex, Inc. | 0001193125-18-019836 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2017-06-02 | S-1/A | registration statement | $11.00–$13.00 | $6.25 | 6,000,000 | $37,500,000 | Nasdaq ATNX | 4 | primary document; range, price line, shares headline, proceeds computed, cover names 4 | document ↗ |
| 2017-06-15 | 424B4 | final prospectus | $11.00 | 6,000,000 | $66,000,000 | Nasdaq ATNX | 4 | primary document; price sentence, shares headline, proceeds table, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Beansprouts Ltd | Director; TenPercentOwner | 22 | 2017–2018 | ||
| CAMPBELL KIM | Director | 10 | 2017–2021 | ||
| CANNON MICHAEL D | Director; Other | 4 | 2017–2018 | ||
| Fok Manson | Director | 21 | 2017–2023 | ||
| Kwan Rudolf | Director,Officer; Officer | EVP, Chief Medical Officer | 53 | 2017–2023 | |
| LAU JOHNSON YIU NAM | Director,Officer; Director,Officer,TenPercentOwner | CEO and Chairman of the Board; See Remarks | 108 | 2017–2023 | |
| Leung Antony | Director | 2 | 2017 | ||
| Mandra Medical Ltd | Director; TenPercentOwner | 22 | 2017–2018 | ||
| Mui Bing How Tammy | Director; TenPercentOwner | 22 | 2017–2018 | ||
| Pedder Simon | Officer | See Remarks; See Remarks. | 10 | 2017–2021 | |
| Riehle J Nick | Officer; Other | Chief Financial Officer | 4 | 2017–2018 | |
| Trainor-Degirolamo Sheldon | Director | 13 | 2017–2019 | ||
| WU JINN | Director | 32 | 2017–2023 | ||
| YORDON JEFFREY | Officer | See Remarks | 14 | 2017–2022 | |
| Zhang Song-Yi | Director; Director,TenPercentOwner | 28 | 2017–2019 | ||
| Zukin James | Director; Other | 4 | 2017–2018 | ||
| Zuo William Wei | Officer | President, China; President, China Division | 12 | 2017–2021 | |
| Advance Data Services Ltd | TenPercentOwner | 1 | 2017 | ||
| Ma Huateng | TenPercentOwner | 1 | 2017 | ||
| Shen Li | Officer | See Remarks; See Remarks. | 2 | 2018 | |
| TSANG Benson Kwan Hung | Director | 14 | 2018–2023 | ||
| Sze Randoll | Officer | Chief Financial Officer | 10 | 2018–2020 | |
| Davis Stephanie A | Director | 15 | 2019–2023 | ||
| Kanfer Jordan | Director | 10 | 2019–2022 | ||
| VIERLING JOHN | Director | 14 | 2019–2023 | ||
| Koh John | Director | 4 | 2019–2020 | ||
| EDELMAN JOSEPH | TenPercentOwner | 15 | 2019–2020 | ||
| PERCEPTIVE ADVISORS LLC | TenPercentOwner | 15 | 2019–2020 | ||
| PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | TenPercentOwner | 15 | 2019–2020 | ||
| Bair Teresa Brophy | Officer | General Counsel, SVP Admin. | 4 | 2020–2021 | |
| Spiegel Robert J. | Director | 10 | 2020–2023 | ||
| Adams Steven J. | Officer | Interim Chief Acct Officer | 2 | 2021 | person page Fuzzy |
| Smolinski Michael | Officer | Chief Scientific Officer | 2 | 2021–2022 | |
| Lang Daniel | Officer | Pres Cell Therapy, VP Corp Dev | 3 | 2021–2022 | |
| Cook Timothy DeVere | Officer | See Remarks | 33 | 2022–2023 | |
| Annoni Joe | Officer | Chief Financial Officer | 4 | 2022–2023 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2019-12-11 | Athenex, Inc. | Pharmaceuticals | $60,369,975 | $60,369,975 | 5 | 1 |
| 2019-05-15 | Athenex, Inc. | Pharmaceuticals | $100,000,000 | $100,000,000 | 4 | 1 |
| 2018-07-17 | Athenex, Inc. | Pharmaceuticals | $50,000,000 | $50,000,000 | 1 | 1 |
| 2017-05-03 | Athenex, Inc. | Biotechnology | $20,000,000 | $20,000,000 | 1 | 1 |
| 2016-10-07 | Athenex, Inc. | Biotechnology | $50,000,000 | $37,900,000 | 5 | 1 |
| 2015-06-16 | Kinex Pharmaceuticals, Inc. | Biotechnology | $10,000,016 | $10,000,016 | 2 | 1 |
| 2015-05-20 | Kinex Pharmaceuticals, Inc. | Biotechnology | Indefinite | $74,399,996 | 9 | 2 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Plan sponsor | ATHENEX INC. | NY | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Form D issuer | Athenex, Inc. | NY | Form D private offerings | CIK (EXACT) |
| SEC filer | Athenex, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Business registration | ATHENEX, INC | State business registries | name and state | |
| Business registration | ATHENEX, LLC | State business registries | name and state | |
| Form 5500 plan sponsor | ATHENEX, INC. | EIN (EXACT) | ||
| Person page | Steven J Adams | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Officer) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, NY first:
- TG THERAPEUTICS, INC. NY
- SIGA TECHNOLOGIES INC NY
- SEELOS THERAPEUTICS, INC. NY
- Protagenic Therapeutics, Inc.\new NY
- XTL BIOPHARMACEUTICALS LTD NY
- PENWEST PHARMACEUTICALS CO NY
- CHEMBIO DIAGNOSTICS, INC. NY
- EYETECH PHARMACEUTICALS INC NY
- INNOVATIVE DRUG DELIVERY SYSTEMS INC NY
- EON LABS INC NY
In other datasets, the same topic (Health) in NY:
- Nonprofit: AABR FOUNDATION INC (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health